Eli Lilly announced acquisitions of Curevo Inc., LimmaTech Biologics AG, and Vaccine Company, Inc., investing up to $3.8 billion to enhance its infectious disease research and vaccine development. These deals align with Lilly's strategy to prevent diseases linked to infections, including neurological disorders, cancer, and antibiotic-resistant bacteria. Curevo's shingles vaccine is in Phase 2 trials, while LimmaTech targets drug-resistant bacteria, and Vaccine Company focuses on nanoparticle vaccines like Epstein-Barr Virus. The acquisitions support Lilly's long-term goal of disease prevention rather than just treatment, with regulatory approvals pending.
Eli Lilly announced it will acquire three vaccine developers—Curevo, LimmaTech Biologics AG, and Vaccine Company—in deals totaling up to $3.83 billion. This strategic move expands Lilly's focus into infectious disease prevention, complementing its ex...
Lilly has agreed to acquire Curevo Vaccine, a biotech firm developing a next-generation shingles vaccine called amezosvatein, designed to improve tolerability and increase vaccination rates. The deal could pay Curevo shareholders up to $1.5 billion, ...
Eli Lilly announced plans to acquire Curevo, LimmaTech Biologics, and Vaccine Company for a total of nearly $4 billion in cash. This move aims to expand Eli Lilly's research and development efforts into infectious diseases, focusing on preventing dis...
Eli Lilly announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company to expand its infectious disease research. These acquisitions focus on developing vaccines targeting viral and bacterial pathogens linked to long-term health r...
Eli Lilly reported positive Phase 1b results for VERVE-102, a gene therapy that permanently silences the PCSK9 gene to reduce LDL cholesterol by up to 62%. The therapy showed sustained effects for up to 18 months and was well-tolerated with no seriou...
